Renovaro (RENB) Stock Price, News & Analysis

Company Overview

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $0.23 to $0.25
• 50-Day Range: $0.23 to $0.37
• 52-Week Range: $0.22 to $2.10
• Volume: 642,047 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $41.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed this year?

Renovaro's stock was trading at $0.8355 at the start of the year. Since then, RENB stock has decreased by 71.4% and is now trading at $0.2390.

How were Renovaro's earnings last quarter?

Renovaro Inc. (NASDAQ:RENB) posted its quarterly earnings data on Wednesday, February, 19th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Who are Renovaro's major shareholders?

Top institutional investors of Renovaro include Geode Capital Management LLC (0.59%), Jane Street Group LLC (0.52%), Marshall Wace LLP (0.18%) and Qube Research & Technologies Ltd (0.13%).
View institutional ownership trends.

How do I buy shares of Renovaro?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Renovaro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renovaro investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 9/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RENB
• CIK: 1527728
• Web: www.enochianbio.com
• Phone: 305-918-1980
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.38%
• Return on Assets: -47.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 172,120,000
• Free Float: 171,258,000
• Market Cap: $41.14 million
• Optionable: Optionable
• Beta: 0.54